Modern Rheumatology

pp 1–4

Successful leukocytapheresis therapy in a patient with rheumatoid arthritis on maintenance hemodialysis

Authors

  • Keisuke Maeshima
    • Department of Internal Medicine I, Faculty of MedicineOita University
  • Masataka Torigoe
    • Department of Internal Medicine I, Faculty of MedicineOita University
  • Mikako Iwakura
    • Department of Internal Medicine I, Faculty of MedicineOita University
  • Kunitoshi Yamanaka
    • Department of Internal MedicineNakatsu Daiichi Hospital
    • Department of Internal Medicine I, Faculty of MedicineOita University
Case Report

DOI: 10.1007/s10165-013-0869-0

Cite this article as:
Maeshima, K., Torigoe, M., Iwakura, M. et al. Mod Rheumatol (2013). doi:10.1007/s10165-013-0869-0
  • 74 Views

Abstract

We report the case of a 44-year-old female undergoing maintenance hemodialysis in whom early-phase rheumatoid arthritis (RA) was successfully treated by leukocytapheresis (LCAP). The effects of prednisone, tacrolimus, and etanercept were limited, but LCAP was highly effective and its efficacy continued even after cessation of LCAP. Moreover, remission was maintained for 2 years after discontinuation of medication. LCAP may be an important treatment option for RA patients with end-stage renal failure who are on hemodialysis.

Keywords

Leukocytapheresis (LCAP)Rheumatoid arthritisHemodialysisDrug-free remission

Copyright information

© Japan College of Rheumatology 2013